Capital Performance Advisors LLP Protalix Bio Therapeutics, Inc. Transaction History
Capital Performance Advisors LLP
- $310 Million
- Q4 2024
A detailed history of Capital Performance Advisors LLP transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Capital Performance Advisors LLP holds 25,976 shares of PLX stock, worth $64,420. This represents 0.02% of its overall portfolio holdings.
Number of Shares
25,976
Previous 25,976
-0.0%
Holding current value
$64,420
Previous $26,000
88.46%
% of portfolio
0.02%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding PLX
# of Institutions
51Shares Held
3.58MCall Options Held
61.1KPut Options Held
36.2K-
Jim Simons Renaissance Technologies LLC | New York, Ny956KShares$2.37 Million0.0% of portfolio
-
Gsa Capital Partners LLP London, X0435KShares$1.08 Million0.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny374KShares$926,9170.0% of portfolio
-
Black Rock Inc. New York, NY333KShares$826,2640.0% of portfolio
-
Stratos Wealth Partners, Ltd.270KShares$669,6000.01% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $123M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...